<DOC>
	<DOCNO>NCT03066830</DOCNO>
	<brief_summary>Primary Objective : To demonstrate superiority sotagliflozin 400 mg versus placebo Hemoglobin A1c ( HbA1c ) reduction Week 26 patient type 2 diabetes ( T2D ) inadequate glycemic control sulfonylurea alone combination metformin . Secondary Objectives : - To compare sotagliflozin 400 mg versus placebo base : - Change baseline fast plasma glucose ( FPG ) . - Change baseline systolic blood pressure ( SBP ) patient baseline SBP ≥130 mm Hg . - Change baseline SBP patient . - Change baseline body weight . - Proportion patient HbA1c &lt; 6.5 % &lt; 7.0 % . - To evaluate safety sotagliflozin 400 mg versus placebo throughout 79-week trial .</brief_summary>
	<brief_title>Efficacy Safety Sotagliflozin Versus Placebo Patients With Type 2 Diabetes Mellitus Background Sulfonylurea Alone With Metformin</brief_title>
	<detailed_description>The duration per patient 85 week , include Screening Period consist Screening phase 2 week 2-week single-blind Run-in phase , 26-week double blind Core Treatment Period , 53 week double blind Extension , 2-week post treatment Follow-up period collect safety information .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Patients T2D treat sulfonylurea ( ≥half maximum recommend dose per local label maximum tolerate dose [ document ] ) monotherapy combination metformin ( ≥1500 mg per day maximum tolerate dose [ document ] ) stable dose least 12 week without dose adjustment screening . Signed write informed consent . Exclusion criterion : At time screening , age &lt; 18 year &lt; legal age majority , whichever great . Body Mass Index ( BMI ) ≤20 &gt; 45 kg/m² Screening Hemoglobin A1c ( HbA1c ) &lt; 7 % HbA1c &gt; 10 % via central lab test screening . Fasting plasma glucose ( FPG ) &gt; 15 mmol/L ( 270 mg/dL ) measure central laboratory screening ( Visit 1 ) , confirm ( &gt; 15 mmol/L [ 270 mg/dL ] ) repeat test randomization . Women childbearing potential effective contraceptive method . Treated antidiabetic pharmacological regimen sulfonylurea stable dose without metformin within 12 week precede screen visit . Previous insulin use &gt; 1 month ( time , aside treatment gestational diabetes ) . History prior gastric surgical procedure include gastric band inflammatory bowel disease within 3 year Screening Visit . History diabetic ketoacidosis nonketotic hyperosmolar coma within 12 week prior Screening Visit . History severe hypoglycemia within 6 month prior Screening visit . Systolic blood pressure ( SBP ) &gt; 180 mmHg diastolic blood pressure ( DBP ) &gt; 100 mmHg history hypertensive emergency . Aspartate aminotransferase and/or alanine aminotransferase : &gt; 3 time upper limit normal laboratory range ( ULN ) . Total bilirubin : &gt; 1.5 time ULN ( except case Gilbert 's syndrome ) . Use systemic glucocorticoid ( exclude topical ophthalmic , application inhale form ) 10 consecutive day within 90 day prior Screening Visit . Pregnancy , breastfeed . Patient unwilling perform selfmonitoring blood glucose ( SMBG ) , complete patient 's diary require per protocol . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>